Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
NCT04797780
Recruiting
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Myelodysplastic Syndromes
Register for Updates
M2VA Pain Care Pathway
NCT06526143
Recruiting
The goal of this 2-cohort, cluster randomized, type 2 hybrid trial is to test the effectiveness, cost-effectiveness and patient-level effects of an implementation facilitation strategy in helping M2VA case managers adopt a Military2VA Pain Care Pathway (M2VAPCP) intervention. The main questions it aims to answer are: Will adding implementation facilitation to training-as-usual for M2VAPCP result in a higher proportion of Veterans who receive M2VAPCP compared to training-as-usual alone? Will ad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: VA Connecticut Healthcare System (VACHS), West Haven, Connecticut
Conditions: Pain, Substance Use, Opioid Misuse, Quality of Life
Register for Updates
Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT03991962
Recruiting
The purpose of this study is to evaluate the efficacy of modified FOLFIRINOX followed by stereotactic body radiotherapy (SBRT) in patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC). The primary hypothesis will be to determine if modified FOLFIRINOX followed by SBRT improves progression free survival (PFS) compared to historical controls treated with gemcitabine-based chemotherapy with or without standard fractionated radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Pancreatic Cancer
Register for Updates
PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults
NCT05906511
Recruiting
The overarching goal of this double-blind, placebo-controlled, crossover study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) effects of the main analgesic and psychoactive constituent of cannabis, delta-9 tetrahydrocannabinol (THC), among older adults - the fastest growing population of cannabis consumers, and the most likely age cohort to use cannabinoids to relieve pain. The research will proceed with a sub-study, randomizing 20 men and women aged 65 years or older, to t... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
11/06/2024
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Pain, Tolerance, Oral vs Vaporized THC, Abuse Liability
Register for Updates
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Register for Updates
Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee
NCT05059626
Recruiting
Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis. Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
11/04/2024
Locations: The John B. Pierce Laboratory, New Haven, Connecticut
Conditions: Endometriosis
Register for Updates
Sipuleucel-T Combined with Bipolar Androgen Therapy in Men with MCRPC
NCT06100705
Recruiting
This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor which the activated autologous dendritic cells in the Sipuleucel-T vaccine are loaded with) in patients with metastatic castration resistant prostate ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
NCT06523777
Recruiting
The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center, Bridgeport, Connecticut
Conditions: Prostate Cancer
Register for Updates
Intranasal Insulin for Posttraumatic Stress Disorder
NCT04044534
Recruiting
To evaluate if intranasal insulin is effective in reducing PTSD symptoms.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
10/31/2024
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: PTSD
Register for Updates
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04696731
Recruiting
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Register for Updates
Food for Thought - a Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
NCT06582615
Recruiting
The goal of this randomized clinical trial is to learn if a healthy eating pattern called the MIND eating plan can reduce cancer-related cognitive impairment (commonly called "chemobrain") and other symptoms commonly experienced by women with newly diagnosed stage II-III triple negative breast cancer as they go through chemotherapy. The symptoms that will be measured include changes in memory and mental function, fatigue, sleep quality, anxiety, and depression. Researchers will compare measures... Read More
Gender:
FEMALE
Ages:
Between 40 years and 65 years
Trial Updated:
10/29/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Triple-Negative Breast Carcinoma
Register for Updates
The DRAGON 2 Trial
NCT05428735
Recruiting
In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
Register for Updates